A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer
Posted Date: Aug 16, 2017
- Investigator: Muhammad Riaz
- Specialties: Hematology/Oncology, Oncology, Cancer
- Type of Study: Drug
The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.
To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed With Surgery Or Has Spread To Other Areas Of The Body.
A091305, Thyroid Cancer, Cancer, Advanced Anaplastic Thyroid Cancer, Head & Neck
For More Information:
Uc Cancer Institute